Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRD Cancer”

95 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 95 results

Testing effectiveness (Phase 2)Looking for participantsNCT04954599
What this trial is testing

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Maastricht University Medical Center 126
Testing effectiveness (Phase 2)UnknownNCT04499118
What this trial is testing

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
Sichuan Provincial People's Hospital 100
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Early research (Phase 1)Looking for participantsNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Pamela Munster 18
Large-scale testing (Phase 3)Looking for participantsNCT06954584
What this trial is testing

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Tongji Hospital 424
Not applicableStudy completedNCT03159572
What this trial is testing

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 996
Testing effectiveness (Phase 2)Looking for participantsNCT07162051
What this trial is testing

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Xijing Hospital 28
Large-scale testing (Phase 3)Ended earlyNCT00448266
What this trial is testing

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 12
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Large-scale testing (Phase 3)Looking for participantsNCT05659381
What this trial is testing

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Who this might be right for
Stage III Ovarian CancerStage IV Ovarian CancerStage III Primary Peritoneal Cancer+3 more
GOG Foundation 220
Testing effectiveness (Phase 2)WithdrawnNCT06365970
What this trial is testing

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Who this might be right for
MMR-D/MSI-H Colorectal Cancers
Ibrahim Halil Sahin
Testing effectiveness (Phase 2)Study completedNCT02354586
What this trial is testing

Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Who this might be right for
Ovarian NeoplasmsOvarian Cancer
Tesaro, Inc. 463
Large-scale testing (Phase 3)Active Not RecruitingNCT03522246
What this trial is testing

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Who this might be right for
Epithelial Ovarian CancerPrimary PeritonealFallopian Tube Cancer+4 more
pharmaand GmbH 1,097
Not applicableNot Yet RecruitingNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Testing effectiveness (Phase 2)WithdrawnNCT04895046
What this trial is testing

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Who this might be right for
HRDCholangiocarcinomaMetastatic Cancer
Walid Shaib, MD
Not applicableUnknownNCT05069818
What this trial is testing

Variance of HRD From Paired Ovarian Cancer

Who this might be right for
Ovarian CancerHRDPlatinum-sensitive Ovarian Cancer
Xiaoxiang Chen 50
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06419179
What this trial is testing

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

Who this might be right for
Small Cell Lung Carcinoma
University of Cologne 29
Early research (Phase 1)Ended earlyNCT03355066
What this trial is testing

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
Biosplice Therapeutics, Inc. 82
Testing effectiveness (Phase 2)UnknownNCT05288127
What this trial is testing

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Who this might be right for
HRD 100 Gene Expression HighTriple Negative Breast Cancer
University of Malaya 55
Load More Results